BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1822 related articles for article (PubMed ID: 26151226)

  • 1. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
    Kirpich IA; Marsano LS; McClain CJ
    Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.
    Jayakumar S; Loomba R
    Aliment Pharmacol Ther; 2019 Jul; 50(2):144-158. PubMed ID: 31149745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.
    Ma J; Zhou Q; Li H
    Nutrients; 2017 Oct; 9(10):. PubMed ID: 29035308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Gut Microbiota and Nonalcoholic Fatty Liver Disease.
    Quigley EM; Monsour HP
    Semin Liver Dis; 2015 Aug; 35(3):262-9. PubMed ID: 26378643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH.
    Svegliati-Baroni G; Patrício B; Lioci G; Macedo MP; Gastaldelli A
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
    Cho MS; Kim SY; Suk KT; Kim BY
    J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
    Lambert JE; Parnell JA; Eksteen B; Raman M; Bomhof MR; Rioux KP; Madsen KL; Reimer RA
    BMC Gastroenterol; 2015 Dec; 15():169. PubMed ID: 26635079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an
    Carbajo-Pescador S; Porras D; García-Mediavilla MV; Martínez-Flórez S; Juarez-Fernández M; Cuevas MJ; Mauriz JL; González-Gallego J; Nistal E; Sánchez-Campos S
    Dis Model Mech; 2019 Apr; 12(5):. PubMed ID: 30971408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
    Meroni M; Longo M; Dongiovanni P
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiome and nonalcoholic fatty liver diseases.
    Zhu L; Baker RD; Baker SS
    Pediatr Res; 2015 Jan; 77(1-2):245-51. PubMed ID: 25310763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota.
    Doulberis M; Kotronis G; Gialamprinou D; Kountouras J; Katsinelos P
    Metabolism; 2017 Jun; 71():182-197. PubMed ID: 28521872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
    World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional Interactions between Gut Microbiota Transplantation, Quercetin, and High-Fat Diet Determine Non-Alcoholic Fatty Liver Disease Development in Germ-Free Mice.
    Porras D; Nistal E; Martínez-Flórez S; Olcoz JL; Jover R; Jorquera F; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Mol Nutr Food Res; 2019 Apr; 63(8):e1800930. PubMed ID: 30680920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease.
    Koukias N; Buzzetti E; Tsochatzis EA
    Minerva Endocrinol; 2017 Jun; 42(2):184-194. PubMed ID: 27879962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut Microbiota: Association with NAFLD and Metabolic Disturbances.
    Lau E; Carvalho D; Freitas P
    Biomed Res Int; 2015; 2015():979515. PubMed ID: 26090468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target.
    Kessoku T; Kobayashi T; Tanaka K; Yamamoto A; Takahashi K; Iwaki M; Ozaki A; Kasai Y; Nogami A; Honda Y; Ogawa Y; Kato S; Imajo K; Higurashi T; Hosono K; Yoneda M; Usuda H; Wada K; Saito S; Nakajima A
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity, fatty liver disease and intestinal microbiota.
    Arslan N
    World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 92.